Meropenem Steriscience (Meropenem)

Meropenem exerts its antibacterial effect by binding to penicillin‑binding proteins on the bacterial cell wall, blocking the final step of peptidoglycan cross‑linking. This inhibition weakens the cell wall, causing osmotic lysis and rapid bactericidal activity against a broad spectrum of Gram‑negative and Gram‑positive organisms, including many resistant strains.

The dosage of Meropenem Steriscience is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and local susceptibility patterns. Dosing regimens are individualized and should follow current clinical guidelines and the prescriber’s judgment.

Safety data for Meropenem in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential therapeutic benefit justifies the possible risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the Meropenem Steriscience product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and required import documentation.

Meropenem offers a broad spectrum of activity, including stability against many beta‑lactamases, and penetrates the central nervous system better than some carbapenems, making it useful for meningitis. Compared with imipenem‑cilastatin, it has a lower risk of seizures. It is often chosen over cephalosporins when organisms produce extended‑spectrum beta‑lactamases or when multidrug‑resistant pathogens are suspected.

Meropenem Steriscience must be stored at 2‑8 °C, kept refrigerated, protected from light, and should never be frozen or shaken. Prior to use, inspect the solution for particulate matter or discoloration and discard if any abnormalities are observed.

The product is supplied as an injectable solution for intravenous infusion. It is typically administered over 15‑30 minutes using a sterile IV set. Infusion rate and duration should be guided by the prescribing clinician, and the solution should be used promptly after preparation to maintain stability.

Serious adverse events include seizures (particularly in patients with renal dysfunction or CNS disease), anaphylactic or severe hypersensitivity reactions, Clostridioides difficile‑associated colitis, neutropenia, and acute renal impairment. Prompt recognition and discontinuation of therapy are essential if any of these events occur.

Meropenem Steriscience is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation. Caution is also advised for individuals with severe renal impairment who have not received appropriate dose adjustments, and for patients with a history of seizures unless benefits outweigh risks.